Salah Hadi
Overview
Explore the profile of Salah Hadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moullan N, Asiago J, Stecco K, Hadi S, Albizem M, Tieu H, et al.
Infect Dis Ther
. 2024 Jan;
13(1):173-187.
PMID: 38221576
Introduction: COVID-19 remains a significant risk for the immunocompromised given their lower responsiveness to vaccination or infection. Therefore, passive immunity through long-acting monoclonal antibodies (mAbs) offers a needed approach for...
2.
Vissers M, Heuberger J, Groeneveld G, Oude Nijhuis J, De Deyn P, Hadi S, et al.
Clin Transl Sci
. 2022 Jun;
15(8):2010-2023.
PMID: 35649245
RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1...
3.
Sturm S, Delporte M, Hadi S, Schobel S, Lindemann L, Weikert R, et al.
Br J Clin Pharmacol
. 2017 Nov;
84(3):445-455.
PMID: 29096426
Aim: The objectives of this first-in-human study were to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and maximum tolerated dose (MTD) of single ascending oral doses of RG7342, a...
4.
Van der Ree M, de Vree J, Stelma F, Willemse S, Van Der Valk M, Rietdijk S, et al.
Lancet
. 2017 Jan;
389(10070):709-717.
PMID: 28087069
Background: miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of...
5.
Stockis A, Hartstra J, Mollet M, Hadi S
Epilepsia
. 2016 Jun;
57(8):1288-93.
PMID: 27346728
Objective: To determine the bioequivalence of brivaracetam oral tablet formulations (10, 75, and 100 mg) versus 50 mg oral tablet and to compare the bioavailability of brivaracetam 100 mg intravenous...